The Phase 1 trial demonstrated the safety and tolerability of Locteron given as a single dose to healthy volunteers, and the pharmacokinetic and pharmacodynamic results support dosing every two weeks,a substantial improvement over currently marketed pegylated interferons that require dosing every week.
The phase 1 clinical trial data of Locteron was presented by the research team at the Annual Meeting of the European Association for the Study of Liver Disease (EASL) meeting in Vienna, Austria.
Source: Biolex Therapeutics
.jpg)
Comment Preview